Compare Inovio Pharmaceuticals Inc (INO) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Quantum Computing Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while Quantum Computing Inc trades at $7.41 (market cap $1.69B). The key difference: Quantum Computing Inc is far larger — about 15.1× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Quantum Computing Inc for 25 Days on average.
| INO | QUBT | |
|---|---|---|
Market Cap | $112.19M | $1.69B |
Volume | 3,201,278 | 7,991,522 |
Sector | Health | Technology |
52-Week High | $2.65 | $21.78 |
52-Week Low | $0.66 | $6.31 |
Typical Hold Time | 43 Days | 25 Days |
Enterprise Value | $83.51M | $753.24M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
Quantum Computing Inc. (QUBT) trades at $7.43, down 2.49% today, with a bearish technical signal despite bullish oscillators. The company shows explosive revenue growth from $682K in 2025 to $10M projected for 2026, but remains deeply unprofitable with a -152.45% net income margin. Recent developments include the Dirac-3S quantum system launch and a $42.5M backlog, though rising expenses and shareholder litigation create headwinds.
QUBT offers speculative growth potential in quantum computing with strong analyst support (75% buy rating, $17.33 target) but faces significant execution risks. The stock's appeal hinges on commercializing quantum technology amid persistent losses and competitive threats, requiring careful risk assessment by growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
